REVANCE - Key Persons
Job Titles:
- Chief People Officer
- Professor at California Lutheran University
Amie Krause joined Revance in March 2023 as Chief People Officer, overseeing human resources and people functions, including culture initiatives, employee relations, total rewards, diversity and inclusion, leadership development, talent acquisition, as well as corporate affairs.
Amie has over 25 years of experience in the biotech industry as a senior human resources leader. Prior to joining Revance, she was the SVP and Chief People Officer at Atara Biotherapeutics in Thousand Oaks, CA where she led people strategies, company growth, culture and employee development. Prior to Atara, Amie worked for Amgen in a number of human resources roles of increasing responsibility, including her role as Global HR Lead, Organizational Effectiveness during which she served as the Human Resources Leader for Amgen's global commercial operations covering the Americas, Europe, Asia, and the Middle East. Prior to Amgen, Amie held multiple Talent Acquisition roles, in the services, and gaming industries.
Amie is a professor at California Lutheran University, School of Business and teaches part of their MBA curriculum. She has served in Civic roles and has been a guest lecturer and speaker for various conferences including the Healthcare Businesswomen's Association. Amie resides in Nashville with her husband Michael. Outside of work Amie enjoys movies, nature hikes, working out, and spending time with friends and family. Amie holds both a B.S. in Business Management and an MBA in Organizational Management from California Lutheran University.
Job Titles:
- CHAIRMAN of the BOARD
- Chairman of the NOMINATING and GOVERNANCE COMMITTEE
- Director
- Member of the Compensation Committee
- Member of the Nominating and Corporate Governance Committee
- CHAIRMAN of the BOARD / CHAIR, NOMINATING and GOVERNANCE COMMITTEE
Angus Russell has served as a director and Chairman of the Board since March 2014. Mr. Russell is a veteran in the global biopharmaceutical industry with more than 30 years' experience in commercial execution, operations, and strategic acquisitions. He was the Chief Executive Officer of Shire plc, a biopharmaceutical company focused on the development of therapies for the treatment of rare and specialty conditions, from June 2008 until April 2013, Shire's Chief Financial Officer from 1999 to 2008, and a member of its board of directors from 1999 until 2013. While CEO at Shire, Mr. Russell was also the Chair of Shire's Leadership Team and a lead member of the Shire Management Committee, which designed and implemented the company's immensely successful long-term business strategy. Prior to joining Shire, Mr. Russel served at AstraZeneca plc, a pharmaceutical and biologics company, most recently as VP of Corporate Finance. Mr. Russell served on the Board of Directors of Mallinckrodt from August 2014 to June 2022 and of TherapeuticsMD, Inc. from March 2015 to December 2022. Mr. Russell has also served on the board of directors of Lineage Cell Therapeutics, Inc. (formerly known as BioTime, Inc.), since December 2014.
Job Titles:
- Member of the Audit Committee
Job Titles:
- Chairman of the Audit Committee
- Director
- Member of the Nominating and Corporate Governance Committee
- Retired Audit Partner at Ernst & Young
Chris Nolet has served as a director since July 2019 and is Chair of the Audit Committee. Mr. Nolet is a retired audit partner at Ernst & Young. In addition to serving clients, his responsibilities include leading the West EY Life Sciences Industry Group and serving as a member of the Global EY Life Sciences Executive Leadership Group, which establishes policies and operating strategies for EY's $2 billion practice worldwide. He serves on both the Executive Committee and Audit Committee (Chair) of the California Life Sciences Industry Association (CSLA) for the past 18 years and is a former member of the Finance & Investment Committee and Emerging Companies Section of BIO (the Biotechnology Innovation Organization). Mr. Nolet currently serves on the board of directors of Jasper Therapeutics (NASDAQ - JSPR), a biotechnology company. He also served on the board of directors of Viela Bio, Inc. until March 2021, Ambrx Biopharma Inc. until November of 2021 and PolarityTE until January of 2023. Mr. Nolet is a featured speaker at the annual Davis Polk IPO conference and has testified before congress regarding the need for FDA reform. He is a CPA (California) and member of the AIPCA and the California Society of CPAs. Additionally, Mr. Nolet served on the School of Accountancy Advisory Board at his alma mater San Diego State University, where he received his B.S. in Accounting.
Job Titles:
- CHIEF MEDICAL OFFICER, GLOBAL THERAPEUTICS FRANCHISE LEAD
David A. Hollander, M.D., M.B.A., joined Revance in October 2022 as Chief Medical Officer, overseeing clinical development, data science, medical affairs, scientific innovation, pharmacovigilance and regulatory affairs.
Dr. Hollander brings over 20 years of experience in the global biotech and pharma industry, spanning the entire drug development life cycle. Prior to joining Revance, he was the Chief Research & Development Officer at Aerie Pharmaceuticals, where he directed preclinical research and clinical development in the U.S., Europe and Japan, and led the company's medical affairs, regulatory and quality organizations. Previously, he was the Chief Medical Officer at Ora, Inc., where he oversaw medical operations across pharmaceutical and device clinical development, preclinical studies, as well as research and development into new regulatory endpoints. Dr. Hollander began his industry career at Allergan, Inc., where he spent a decade serving in roles of increasing responsibility, including Vice President, Global Therapeutic Area Head in Clinical Development for Anterior Segment and Consumer Eye Care. Dr. Hollander currently serves as a Board Member for Kiora Pharmaceuticals and the Arnold & Mabel Beckman Foundation.
Dr. Hollander received his B.S. in chemistry with honors and distinction from Stanford University, earned his medical degree at the University of Pennsylvania School of Medicine, and obtained an M.B.A. in Health Care Management from the Wharton School. He completed his residency in ophthalmology at the University of California, San Francisco, and a Heed Fellowship in Cornea, External Disease, and Refractive Surgery at the Jules Stein Eye Institute, University of California, Los Angeles.
Job Titles:
- Director
- Member of the Compensation Committee
- Associate Clinical Professor of Psychiatry at the Yale School of Medicine
- Chairman and CEO of Biohaven
Vlad Coric has served as a director since March 2023. Dr. Coric is currently the Chairman and CEO of Biohaven, where he has successfully led the approval and commercialization of its Nurtec® ODT and CGRP franchise in addition to the expansion of company's therapeutic portfolio targeting neurological and neuropsychiatric diseases. He also led Biohaven's acquisition of its novel Kv7 channel platform and the sale of the Biohaven to Pfizer in October 2022 for total considerations of $13 billion. Previously, Dr. Coric was the Group Director, Neuroscience and Oncology Global Clinical Research, and Medical Director, Neuroscience Global Clinical Research, at Bristol-Myers Squibb Company. He also previously served on the board of directors of Social Capital Suvretta Holdings Corp. I (DNAA) from 2021-2022 and he currently serves on the boards of directors of private biotech companies including Veradermics, Inc., Vita Therapeutics, Inc., and Pyramid Biosciences, Inc.
During his career, Dr. Coric has been involved in multiple drug development programs, including marketed drugs or filed NDAs such as Nurtec ODT (rimegepant; oral calcitonin related peptide antagonist), zavegepant (intranasal calcitonin related peptide antagonist), Abilify® (aripiprazole; partial dopamine agonist), Opdivo® (nivolumab; anti-PD1), Yervoy® (Ipilimumab; anti-CTLA-4), Daklinza® (daclatasvir; NS5A inhibitor), and Sunvepra® (asunaprevir; NS3 inhibitor).
Dr. Coric is an Associate Clinical Professor of Psychiatry at the Yale School of Medicine, has published over 65 peer-reviewed publications and has lectured nationally on neurological and psychiatric disorders. He earned his medical degree from Wake Forest University School of Medicine and was an honors scholar in neurobiology and physiology at the University of Connecticut, where he received his Bachelor of Science degree.
Job Titles:
- Chief Legal Officer
- General Counsel
- in 2020 As Corporate Secretary to the Board
Dwight O. Moxie joined Revance in 2020 as Corporate Secretary to the Board and as Senior Vice President, General Counsel & Corporate Secretary on the Senior Executive Team. Mr. Moxie leads all legal, governance, and compliance initiatives for Revance.
Erica Jordan - Chief Commercial Officer
Job Titles:
- Chief Commercial Officer
- in 2023 As Senior Vice President
Erica Jordan is Chief Commercial Officer, Aesthetics of Revance, leading commercial activities including commercial strategy, sales operations, and marketing, branding, loyalty and engagement.
Mrs. Jordan joined Revance in 2023 as Senior Vice President, Commercial, bringing 25 years of marketing, sales management, commercial strategy, commercial operations and management experience at leading global healthcare companies. Prior to joining Revance, she served as President of the Metrex division at Envista Holdings, where she developed and executed a successful commercial strategy and implemented operational efficiencies to support double-digital growth. Erica has held several leadership roles in marketing, commercial and operational leadership roles at Phillips Healthcare, Fujifilm Medical Systems, Siemens Medical Solutions, and GE Healthcare. In these roles, Erica has successfully launched multiple products, enabled significant market growth, and transformed organizations for growth.
Erica holds a B.S. in Marketing and Finance from the University of Wisconsin, Milwaukee.
Job Titles:
- Investor Relations Contacts
Job Titles:
- Director
- Member of the Compensation Committee
- Chairman, BRAND COMMITTEE, COMPENSATION COMMITTEE
Jill Beraud has served as a director since June 2019. Ms. Beraud brings more than 25 years' experience building luxury, fashion, beauty, and consumer brands. She was the CEO and Co Founder of Sh'nnong Beverage Company, a business creating a line of functional beverages. She previously served as CEO of IPPOLITA, a fine jewelry company with distribution in Bergdorf Goodman, Neiman Marcus, Nordstrom, and other national retailers. Previously she held the role of Executive Vice President, Global Retail and e Commerce, for Tiffany & Co., where she was responsible for all global retail, operations, e commerce, and omni channel consumer experience. Ms. Beraud has also managed brands such as Living Proof and Starbucks/Lipton Joint Ventures and served as Global Chief Marketing Officer at PepsiCo, where she was responsible for PepsiCo's $60 billion portfolio of food and beverage brands. She also spent 13 years at Limited Brands as Chief Marketing Officer of Victoria's Secret, and Executive Vice President of Marketing for its broader portfolio of specialty brands, including Bath & Body Works, Henri Bendel, and Limited Stores. Further, she has a long history of board membership with iconic brands, including Levi Strauss & Co. Ms. Beraud was named to Fast Company's "Most Creative People in Business" in 2013. She holds a B.S. in Business from Boston University and is a graduate of The Wharton School MBA program.
Job Titles:
- Director
- Member of the Audit Committee
- Chairman of the Board / Lead Independent Director / Committee Chair
Julian S. Gangolli has served as a director since July 2016. He was the President, North America of GW Pharmaceuticals Inc. and President of Greenwich Biosciences Inc., the U.S. subsidiary of GW Pharmaceuticals, spearheading the buildout of the company's U.S. commercial infrastructure in advance of the potential launch of its lead therapeutic candidate, Epidiolex® (cannabidiol or CBD), which is in late-stage development for a number of child-onset epilepsy syndromes. Mr. Gangolli is also a director of GW Pharmaceuticals PLC. Prior to joining GW Pharma, Mr. Gangolli served as President of the North American Pharmaceutical division of Allergan Inc. for 11 years, where he was responsible for a 1,400-person integrated commercial operation with sales exceeding $3.8 billion in 2014. Previously, he served as Senior Vice President, U.S. Eye Care at Allergan, during which time this division launched eight new products, helping to propel growth at more than 20% a year over a 5-year period. Prior to Allergan, Mr. Gangolli served in increasingly senior sales and marketing positions at VIVUS, Inc., Syntex Pharmaceuticals, Inc., and Ortho-Cilag Pharmaceuticals Ltd. in the UK. Mr. Gangolli currently serves as a member of the board of directors of Krystal Biotech, Inc., a clinical-stage gene therapy company, and Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company. Mr. Gangolli received a BSc (Honors) degree in Applied Chemistry and Business Studies from Kingston University in England.
Mark J. Foley is the CEO of Revance Therapeutics and has served as a member of the Company's board of directors since September 2017.
Previously, Mr. Foley was Chairman, President and CEO of ZELTIQ Aesthetics (ZLTQ). During his tenure, he led ZELTIQ's growth from $68 million in annual revenue in 2012 to over $350 million in 2016, resulting in an appreciation of the Company's stock of greater than tenfold and acquisition by Allergan (AGN) in April of 2017 for $2.5B. Mr. Foley also served as a Managing Director of RWI Ventures, a venture capital firm focused on life sciences, networking, semiconductor and software investments, from 2004 to 2018.
Mr. Foley has over 25 years of experience in the health care field, having served in a variety of senior operating roles in both large public companies and venture-backed startups, including U.S. Surgical Corporation, Guidant Corporation, Devices for Vascular Intervention (acquired by Eli Lilly), Perclose (acquired by Abbott) and Ventrica (acquired by Medtronic), where he was the founder and CEO. Also, he has partnered with a number of entrepreneurs to assist with the formation and capitalization of new health care companies while also serving as a Senior Advisor, Executive Chairman, interim CEO and board member to a number of medical device companies.
Mr. Foley currently serves on the board of directors for Glaukos Corp., (GKOS), an ophthalmic medical technology and pharmaceutical company and has served on the board of directors for SI-BONE, a medical device company. He also co-chairs the Aesthetics Innovation Summit and was chairman of Arrinex up and until its acquisition by Stryker in the spring of 2019. Mr. Foley received his BA from the University of Notre Dame and is a named inventor on 17 patent applications.
Job Titles:
- Director
- Member of the Nominating and Corporate Governance Committee
Olivia C. Ware has served as a director since March 2021. Ms. Ware brings more than 21 years of experience in pharmaceutical drug development, commercialization and healthcare management. She was the Senior Vice President, BTK Franchise Head at Principia Biopharma Inc., where she was responsible for developing overall portfolio strategy for the company's three BTKi molecules. She previously served as Senior Vice President, U.S. Market and Franchise Development at Proteus Digital Health, Inc. Ms. Ware also worked in a number of public and private biopharma firms as a private consultant and was the Chief Commercial Officer at CytRx, Inc. Previously, Ms. Ware held various leadership roles at Genentech, Inc. and played a key role in the launch of several commercial drug products, including Rituxan®, Herceptin®, Avastin® and Lucentis®. Her expertise also includes developing managed care, pricing and contracting strategy; developing marketing programs for field-based sales teams; and establishing, growing and optimizing organizations for long-term success. Ms. Ware served as a member of the board of Ambrx Biopharma Inc., a clinical-stage biopharmaceutical company, from April 2021 to June 2022 and has served as a director of Arcellx, Inc. since May 2022. Ms. Ware holds an A.B. in Psychology from Davidson College and an M.B.A. in Finance and Marketing from the University of North Carolina at Chapel Hill.
Tobin C. Schilke joined Revance as Chief Financial Officer in November of 2018. He brings more than 20 years' experience in the global biopharma arena, raising capital, completing mergers and acquisitions (M&A) and providing financial leadership in support of commercial enterprises. From 2016 to 2018 Mr. Schilke served as Chief Financial Officer at Achaogen, Inc., where he raised more than $300 million in capital and built teams and capabilities in financial planning and analysis (FP&A), accounting, procurement, IT and facilities management. Previously, he spent 13 years at Roche/Genentech in a variety of finance and operational roles including CFO of Roche Products Limited in the United Kingdom, Director of Commercial FP&A for Genentech's BioOncology business, and M&A project manager for a number of successful acquisitions, restructurings, and business development initiatives. Mr. Schilke holds a B.S. in Chemical Engineering from Lafayette College, M.S. in Chemical Engineering from University of California, Berkeley, and an M.B.A. from Cornell University.